Sign In
Buy ANVS
$1.77
+0.0200 (+1.14%)
At Close: Jun 22, 2026
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer's Disease
10:10am, Monday, 29'th Apr 2024
MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegener
Wall Street Analysts Believe Annovis Bio (ANVS) Could Rally 197.98%: Here's is How to Trade
10:56am, Wednesday, 24'th Apr 2024
The mean of analysts' price targets for Annovis Bio (ANVS) points to a 198% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analy
Wall Street Analysts See a 218.92% Upside in Annovis Bio (ANVS): Can the Stock Really Move This High?
10:56am, Monday, 08'th Apr 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 218.9% in Annovis Bio (ANVS). While the effectiveness of this highly sought-after metric is questionable, the p
Exploring Automotive Night Vision System Sector Trends Forecast, 2023-2032
02:49am, Friday, 05'th Apr 2024
Market Research Report Automotive Night Vision System Market Size, Share, Competitive Landscape and Trend Analysis: Global Opportunity Analysis and Industry Forecast, 2023-2032 PORTLAND, PROVINCE: ORE
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
07:30am, Tuesday, 02'nd Apr 2024
MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegener
Annovis Announces Publication That Supports Understanding of Buntanetap's Mechanism of Action in Humans
08:00am, Monday, 01'st Apr 2024
Further look at earlier Phase 1b study by ADCS unveils confirmatory data MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company develop
Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 211.71%: Read This Before Placing a Bet
10:56am, Thursday, 21'st Mar 2024
The mean of analysts' price targets for Annovis Bio (ANVS) points to a 211.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ana
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease
07:30am, Wednesday, 20'th Mar 2024
MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced succe
$10 Biotech Stock Wall Street Says Will Be Up Over 200% This Year
09:11am, Friday, 15'th Mar 2024
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored) Are you ready for retirement?
Sell Signal: 3 Stocks to Unload Before the Bubble Bursts
03:33pm, Wednesday, 06'th Mar 2024
As the saying goes, what goes up must come down. This adage holds true for three stocks.
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
08:00am, Tuesday, 27'th Feb 2024
MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel p
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer's Disease
07:30am, Wednesday, 14'th Feb 2024
MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last pa
3 Growth Stocks to Sell in February Before They Bottom
04:06pm, Monday, 12'th Feb 2024
February triggered a rollercoaster ride through the stock market's twists and turns. Amidst the cacophony of growth stocks to sell, three names echo the market with a hint of fundamental caution.
Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects
09:06am, Monday, 12'th Feb 2024
A small sample of patient anecdotes on the internet suggest that buntanetap has some degree of underlying activity in Parkinson's disease (PD). 24-38% of patient anecdotes report a noticeable/measurab
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company's Portfolio
08:00am, Tuesday, 30'th Jan 2024
MALVERN, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the filing o
